Delphia Therapeutics is a biotechnology company pioneering activation lethality, a new area of cancer therapeutics that target cancer's surprising vulnerability to oncogene overactivation. Delphia's activation lethality platform offers the potential for first-in-class targeted cancer medicines that are effective on their own while also combating the emergence of drug resistance to classic targeted therapies.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/19/24 | $67,000,000 | Series A |
Alexandria Venture Investments GV Nextech Invest Polaris Partners | undisclosed |
